SLC6A14-mediated glutamine promotes SYTL4–CXCL8 axis activation to drive gemcitabine resistance and immune evasion in pancreatic cancer
Hyeon Woong Kang, Ju Hyun Kim, Jae Woong Jeong, Sungsoon Fang, Won-Gun Yun, Hye-Sol Jung, Wooil Kwon, Jin-Young Jang, Hyo Jung Kim, Joon Seong Park · 2025
Read SLC6A14-mediated glutamine promotes SYTL4–CXCL8 axis activation to drive gemcitabine resistance and immune evasion in pancreatic cancer by Hyeon Woong Kang, Ju Hyun Kim, Jae Woong Jeong, Sungsoon Fang, Won-Gun Yun, Hye-Sol Jung, Wooil Kwon, Jin-Young Jang, Hyo Jung Kim, Joon Seong Park (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12800172.txt.
Description
Hyeon Woong Kang and co-authors trace how pancreatic cancer cells use a nutrient to resist drugs and hide from the immune system, in a study from 2025. This cancer is famously hard to treat, and the standard drug gemcitabine often stops working. The nutrient glutamine helps tumors survive and shapes a hostile setting around them.
The team found a carrier protein that pulls glutamine into the cells and sits at the center of the process. Its action raises a fuel product that switches on signals raising a shield protein used to evade immune attack. It also drives release of a signal that recruits support cells nearby. Blocking this chain could attack drug resistance and immune hiding at once, the authors argue.
Catalog record
| CREATOR | Hyeon Woong Kang, Ju Hyun Kim, Jae Woong Jeong, Sungsoon Fang, Won-Gun Yun, Hye-Sol Jung, Wooil Kwon, Jin-Young Jang, Hyo Jung Kim, Joon Seong Park |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 79 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |